(19)
(11) EP 4 452 976 A1

(12)

(43) Date of publication:
30.10.2024 Bulletin 2024/44

(21) Application number: 22854249.4

(22) Date of filing: 20.12.2022
(51) International Patent Classification (IPC): 
C07D 471/04(2006.01)
A61P 37/00(2006.01)
 A61P 35/00(2006.01)
A61K 31/437(2006.01)
(52) Cooperative Patent Classification (CPC):
C07D 471/04; A61P 35/00; A61P 37/00
(86) International application number:
PCT/US2022/053479
(87) International publication number:
WO 2023/122072 (29.06.2023 Gazette 2023/26)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA
Designated Validation States:
KH MA MD TN

(30) Priority: 21.12.2021 US 202163292124 P
13.12.2022 US 202263432169 P

(71) Applicant: Principia Biopharma Inc.
Bridgewater, NJ 08807 (US)

(72) Inventors:
  • OWENS, Tim
    Cambridge, Massachusetts 02141 (US)
  • OCHSENBEIN, Philippe E.
    75017 Paris (FR)
  • DIAZ, Krista
    Cambridge, Massachusetts 02141 (US)

(74) Representative: J A Kemp LLP 
80 Turnmill Street
London EC1M 5QU
London EC1M 5QU (GB)

   


(54) CRYSTALLINE FORMS OF (R)-1-(1-ACRYLOYLPIPERIDIN-3-YL)-4-AMINO-3-(4-PHENOXYPHENYL)-1H-IMIDAZO[4,5-C]PYRIDIN-2(3H)-ONE AND SALTS THEREOF